Sugi Predict

Sugi Predict / Targets / SERPINA3

SERPINA3

Alpha-1-antichymotrypsin · P01011 · SERPINA3 on Sugi Atlas →

682 patent compounds predicted against SERPINA3, 102 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL25536678 SCHEMBL25536678 0.59 1/20
SCHEMBL13799128 SCHEMBL13799128 0.54 1/20
SCHEMBL25542552 SCHEMBL25542552 0.54 1/20
SCHEMBL25526895 SCHEMBL25526895 0.54 1/20
SCHEMBL25526914 SCHEMBL25526914 0.54 1/20
SCHEMBL25536730 SCHEMBL25536730 0.53 1/20
SCHEMBL21991323 SCHEMBL21991323 0.53 1/20
SCHEMBL17460986 SCHEMBL17460986 0.53 1/20
SCHEMBL25527037 SCHEMBL25527037 0.53 1/20
SCHEMBL28398140 SCHEMBL28398140 0.52 1/20
SCHEMBL28398141 SCHEMBL28398141 0.52 1/20
SCHEMBL28398142 SCHEMBL28398142 0.52 1/20
SCHEMBL25526930 SCHEMBL25526930 0.52 1/20
SCHEMBL2734676 SCHEMBL2734676 0.51 1/20
SCHEMBL13210484 SCHEMBL13210484 0.51 1/20
SCHEMBL26976933 SCHEMBL26976933 0.51 1/20
SCHEMBL2606973 SCHEMBL2606973 0.51 1/20
SCHEMBL2606986 SCHEMBL2606986 0.51 1/20
SCHEMBL14621985 SCHEMBL14621985 0.51 1/20
SCHEMBL24824202 SCHEMBL24824202 0.51 1/20

Clinical trials — most relevant to SERPINA3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography PHASE4UNKNOWN
Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function PHASE4COMPLETED
Atorvastatin in Acute Stroke Treatment PHASE4COMPLETED
Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency PHASE4RECRUITING
International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema PHASE2/PHASE3COMPLETED
Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency PHASE2/PHASE3COMPLETED
Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection PHASE3WITHDRAWN
Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults PHASE3COMPLETED
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency PHASE3COMPLETED
Phase III, Efficacy and Safety of Kamada-AAT for Inhalation PHASE3RECRUITING
Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury in Patients Undergoing Cardiac Surgery PHASE1/PHASE2UNKNOWN
The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B) PHASE1/PHASE2COMPLETED
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency PHASE1/PHASE2COMPLETED
Safety and Efficacy of Inhaled Alpha-1 Antitrypsin in Preventing Bronchiolitis Obliterable Syndrome in Lung Transplant Recipients PHASE2UNKNOWN
A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD PHASE2COMPLETED
Intravenous Alpha-1 Antitrypsin for Hospitalized Patients With COPD Exacerbations (AECOPD Study) PHASE2NOT_YET_RECRUITING
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC PHASE2RECRUITING
Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation. PHASE2COMPLETED
Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency PHASE2COMPLETED
Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) EARLY_PHASE1UNKNOWN
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease nanACTIVE_NOT_RECRUITING
Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals nanCOMPLETED
Alpha-1 Carrier Genomics Study nanCOMPLETED
Genomic Research in Alpha-1 Antitrypsin Deficiency nanCOMPLETED
PiMZ Longitudinal Cohort (PiMZ Logic) nanRECRUITING
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study nanRECRUITING
Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema nanUNKNOWN
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD) nanCOMPLETED
Belgian Antithrombin Deficiency Registry nanNOT_YET_RECRUITING
Evaluating Genetic Factors That May Contribute to Elastin Function and the Development of Chronic Obstructive Pulmonary Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SERPINA3 binder may also engage these)

ProteinNameSimilarity
Q5R536 — 1.000 Q5R536 →
Q00898 — 0.994 Q00898 →
A6QPQ2 — 0.992 A6QPQ2 →
Q91WP6 — 0.992 Q91WP6 →
P22324 — 0.992 P22324 →
P01009 — 0.991 P01009 →
Q9D7D2 — 0.990 Q9D7D2 →
P61640 — 0.990 P61640 →
P07758 — 0.990 P07758 →
P34955 — 0.990 P34955 →
P05545 — 0.989 P05545 →
P22325 — 0.988 P22325 →
P05543 — 0.988 P05543 →
Q60396 — 0.988 Q60396 →
Q5R9E3 — 0.988 Q5R9E3 →
SERPINA6 Corticosteroid-binding globulin 0.987 landscape →
P26595 — 0.987 P26595 →
Q00896 — 0.987 Q00896 →
P05154 — 0.987 P05154 →
O54762 — 0.987 O54762 →
P01010 — 0.987 P01010 →
Q9TT35 — 0.986 Q9TT35 →
Q03734 — 0.986 Q03734 →
P12725 — 0.986 P12725 →
P22599 — 0.986 P22599 →
Q09055 — 0.986 Q09055 →
Q64118 — 0.986 Q64118 →
Q63969 — 0.986 Q63969 →
Q86WD7 — 0.985 Q86WD7 →
Q9GK37 — 0.985 Q9GK37 →